The pharmaceutical industry is a key driver of scientific and medical progress. It invests billions annually in research and development to develop new medicines. In Europe, the industry invested an estimated €33.6 billion in R&D in 2015 and directly employs over 745,000 people. However, the industry faces challenges from fiscal austerity in Europe and increasing competition from emerging markets with fast-growing pharmaceutical sectors like Brazil and China.
UK medical, pharma and biotech landscape 2013Andrew Porter
This report analyzes data from the Bioscience and Health Technology Database to summarize the state of the UK's life sciences industry in 2013. It finds that the industry consists of 4,980 companies employing 176,000 people, generating £52 billion in total turnover. The medical technology sector is the largest by employment, while the pharmaceutical sector generates the most turnover. Turnover has declined 4% since 2011 due to decreases in pharmaceuticals, but medical technology and biotechnology have seen growth. Employment has declined 2% since 2011. The report provides breakdowns of each sector and trends in employment and turnover.
The pharmaceutical industry in Europe is expected to grow at an annual rate of 3.2% from 2015-2022, driven by new innovations emerging across therapy areas like oncology and immunology. While oncology drugs will account for much of the growth, the top-selling drug in Europe in 2022 is predicted to be Xarelto rather than a cancer drug. Five of the top 10 drugs will treat cancer. However, funding all these new high-cost therapies may challenge healthcare systems. Pharmaceutical companies and payers will need to collaborate more closely on new funding models to support continued innovation.
Heitor Costa presented on the current state of the pharmaceutical industry in Portugal. Key points include:
1) The pharmaceutical industry in Portugal contributes over 1 billion euros annually to the economy and employs over 9,500 workers, though employment has declined 7% from 2008-2010.
2) Clinical trials potential in Portugal is much lower than countries like Belgium, losing Portugal over 136 million euros annually in potential investment compared to Belgium.
3) Access to innovative medicines in Portugal is the lowest compared to other EU countries, with approval delays often several times longer than the legal limits.
This document discusses the state of the biosimilars market and provides insights from a conference on biosimilars. It finds that while biosimilars were initially expected to capture more of the market, positive developments are emerging. Biosimilar approvals and guidelines in regions like Europe and the US could help unlock the market's potential. However, regulatory frameworks remain fragmented globally and biosimilar adoption varies across therapies, countries, and regions. Emerging markets in particular represent opportunities for future biosimilar growth to expand access to biologics.
This document discusses the evolving global biosimilars landscape and opportunities. It notes that after slow initial growth, biosimilars are poised for accelerated growth over the next decade due to expiring biologic drug patents, new US legislation, and payer pressure to reduce costs. By 2015, biosimilars sales are projected to reach $1.9-2.6 billion, up significantly from 2011 levels. Key drivers include major biologics like Herceptin, Enbrel and Humalog losing patent protection and increased focus on areas like oncology, diabetes and rheumatoid arthritis. A diverse range of competitors from generic drugmakers to large biopharmaceutical companies are pursuing biosimilar programs. However, realization of
The Greek pharmaceutical market has faced challenges since 2010 due to austerity measures implemented in response to the financial crisis. Public pharmaceutical expenditures were cut substantially between 2009 and 2013 in an effort to reduce costs. Reforms were implemented including price cuts, changes to pricing systems, increased generic drug usage, and other measures. Total sales in the Greek pharmaceutical market declined in value between 2009 and 2014 for hospitals, pharmacies, and total sales. The top 10 pharmaceutical companies, which are mostly large multinational companies, maintained a majority market share between 2010 and 2013. A SWOT analysis identified strengths for these major companies including established brands and distribution, but also weaknesses like limited profit margins and threats from ongoing financial instability and regulatory changes in Greece.
M&A in pharmaceutical industry between india and italyVishal Singh
This document provides an overview of the pharmaceutical markets in India and Italy. It begins with a summary of the global pharmaceutical market, noting that it grew to $1,324 billion in 2018, with North America making up 48% of the market. India's population growth and rising incomes are making it an attractive emerging market. The pharmaceutical market in India is divided between domestic and export markets. The revenues and lower costs of the Indian pharmaceutical industry make it competitive globally. The document then shifts to provide context on the Italian pharmaceutical market before comparing the two.
UK medical, pharma and biotech landscape 2013Andrew Porter
This report analyzes data from the Bioscience and Health Technology Database to summarize the state of the UK's life sciences industry in 2013. It finds that the industry consists of 4,980 companies employing 176,000 people, generating £52 billion in total turnover. The medical technology sector is the largest by employment, while the pharmaceutical sector generates the most turnover. Turnover has declined 4% since 2011 due to decreases in pharmaceuticals, but medical technology and biotechnology have seen growth. Employment has declined 2% since 2011. The report provides breakdowns of each sector and trends in employment and turnover.
The pharmaceutical industry in Europe is expected to grow at an annual rate of 3.2% from 2015-2022, driven by new innovations emerging across therapy areas like oncology and immunology. While oncology drugs will account for much of the growth, the top-selling drug in Europe in 2022 is predicted to be Xarelto rather than a cancer drug. Five of the top 10 drugs will treat cancer. However, funding all these new high-cost therapies may challenge healthcare systems. Pharmaceutical companies and payers will need to collaborate more closely on new funding models to support continued innovation.
Heitor Costa presented on the current state of the pharmaceutical industry in Portugal. Key points include:
1) The pharmaceutical industry in Portugal contributes over 1 billion euros annually to the economy and employs over 9,500 workers, though employment has declined 7% from 2008-2010.
2) Clinical trials potential in Portugal is much lower than countries like Belgium, losing Portugal over 136 million euros annually in potential investment compared to Belgium.
3) Access to innovative medicines in Portugal is the lowest compared to other EU countries, with approval delays often several times longer than the legal limits.
This document discusses the state of the biosimilars market and provides insights from a conference on biosimilars. It finds that while biosimilars were initially expected to capture more of the market, positive developments are emerging. Biosimilar approvals and guidelines in regions like Europe and the US could help unlock the market's potential. However, regulatory frameworks remain fragmented globally and biosimilar adoption varies across therapies, countries, and regions. Emerging markets in particular represent opportunities for future biosimilar growth to expand access to biologics.
This document discusses the evolving global biosimilars landscape and opportunities. It notes that after slow initial growth, biosimilars are poised for accelerated growth over the next decade due to expiring biologic drug patents, new US legislation, and payer pressure to reduce costs. By 2015, biosimilars sales are projected to reach $1.9-2.6 billion, up significantly from 2011 levels. Key drivers include major biologics like Herceptin, Enbrel and Humalog losing patent protection and increased focus on areas like oncology, diabetes and rheumatoid arthritis. A diverse range of competitors from generic drugmakers to large biopharmaceutical companies are pursuing biosimilar programs. However, realization of
The Greek pharmaceutical market has faced challenges since 2010 due to austerity measures implemented in response to the financial crisis. Public pharmaceutical expenditures were cut substantially between 2009 and 2013 in an effort to reduce costs. Reforms were implemented including price cuts, changes to pricing systems, increased generic drug usage, and other measures. Total sales in the Greek pharmaceutical market declined in value between 2009 and 2014 for hospitals, pharmacies, and total sales. The top 10 pharmaceutical companies, which are mostly large multinational companies, maintained a majority market share between 2010 and 2013. A SWOT analysis identified strengths for these major companies including established brands and distribution, but also weaknesses like limited profit margins and threats from ongoing financial instability and regulatory changes in Greece.
M&A in pharmaceutical industry between india and italyVishal Singh
This document provides an overview of the pharmaceutical markets in India and Italy. It begins with a summary of the global pharmaceutical market, noting that it grew to $1,324 billion in 2018, with North America making up 48% of the market. India's population growth and rising incomes are making it an attractive emerging market. The pharmaceutical market in India is divided between domestic and export markets. The revenues and lower costs of the Indian pharmaceutical industry make it competitive globally. The document then shifts to provide context on the Italian pharmaceutical market before comparing the two.
Market Research Report : Anti diabetic pharmaceuticals market in india 2015 -...Netscribes, Inc.
For the complete report, get in touch with us at: info@netscribes.com
Abstract :
Anti-diabetic pharmaceuticals market in India is considered to be one of the most lucrative diabetes markets in the world. Since India is the second largest diabetic pool in the world, after China, the market is characterized by a huge demand for anti-diabetic drugs. Huge increase in the number of diabetic patients promotes growth of the anti-diabetics pharmaceutical industry. The incidence of diabetes is higher in developed countries because of unhealthy lifestyles . Development of new and innovative drugs is also providing a boost to the market. Comprehensive health insurance coverage fuels the market growth by raising the affordability among patients. Increasing aging population in India increases the prevalence of diabetes, which in turn gives a boost to the drugs market.
However Price regulation in the insulin market and competition from alternative diabetes treatment hinders the growth of Anti-diabetic pharmaceuticals market in India. In spite of substantial demand-supply gap in the insulin market, foreign manufacturers and importers are facing a huge price challenge. Now-a-days People are becoming more aware of diabetes ,and are trying to move away from unhealthy sedentary lifestyles. Increasing awareness on part of the consumers are making them incorporate more physical exercises and avoid junk food. Such consciousness on part of the consumers is decreasing the growth of diabetes, which is limiting the growth of the anti-diabetic pharmaceutical market to some extent. The Indian Government, on its part, has introduced some diabetes control programmes. Various initiatives taken by the government is providing a boost to this market. The market is expected to exhibit steady growth over the next few years.
Table of Contents :
Slide 1: Executive Summary
Macroeconomic Indicators
Slide 2: GDP at Factor Cost: Quarterly (2011-12 – 2014-15), Inflation Rate: Monthly (Dec 2014-Jan 2015 – Mar 2015-Apr 2015)
Slide 3: Gross Fiscal Deficit: Monthly (Feb 2014 – Jul 2014), Exchange Rate: Monthly (Dec 2014 – May 2015)
Slide 4: Lending Rate: Annual (2011-12 – 2014-15), Trade Balance: Annual (2011-12 – 2014-15), FDI: Annual (2009-10 – 2013-14)
Introduction
Slide 5: Types of diabetes
Slide 6: Classification of the diabetes market
Slide 7: Classes of anti-diabetic drugs
Market Overview
Slide 8: Global Anti-Diabetic Pharmaceuticals Market – Overview, Size & Growth
Slide 9: Indian Anti-Diabetic Pharmaceuticals Market – Overview, Size & Growth
Slide 10: Global Diabetes map
Drivers & Challenges
Slide 11: Summary
Slide 12-15: Key Drivers
Slide 16-17: Key Challenges
Government Initiatives
Slide 18: Government programmes
Market Value Chain
Slide 19: Pharmaceutical Value Chain
Slide 20: Multistage Drug Development Process
Regulation and Patents
Slide 21: Drug regulations
Slide 22-23: Drugs approved for marketing in India
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...Office of Health Economics
This research presented in a poster at HTAi 2019, Cologne (Germany) by a team of OHE and IHE researchers, estimates the value added by second generation antipsychotics over their life-cycle in the UK and Sweden. It concludes that considering the entire life-cycle, the value added by SGAs to the system is higher than the expected value estimated at launch. P&R decisions should consider how to measure, capture and take into account the value added by medicines over the long-run.
Author(s) and affiliation(s): Mikel Berdud (Office of Health Economics, London), Niklas Wallin-Bernhardsson (Institute for Health Economics, Stockholm), Bernarda Zamora (Office of Health Economics, London), Peter Lindgren (Institute for Health Economics, Stockholm), Adrian Towse (Office of Health Economics, London)
Event: HTAi 2019 Annual Meeting
Date: 18/06/2019
Location: Cologne, Germany
European union’s medical technology market by emanuel baisireEmanuel Baisire
The document discusses market entry strategies for medical equipment companies entering the European Union market. It analyzes exporting, strategic alliances, and joint ventures. A strategic alliance with a European firm is identified as the best option to gain market knowledge, establish distribution channels, share costs and risks, and comply with regulatory requirements. Manufacturing locally in Europe through the alliance would allow the company to benefit from lower capital costs and currency exchange rates.
Europe biosimilars market opportunity outlook 2020KuicK Research
Europe was the first market to allow commercialization of biosimilars. The European Commission passed legislation in 2004 creating an approval pathway for biosimilars. Safety and efficacy are main concerns for biosimilars in Europe, and the European Medicines Agency requires head-to-head comparisons to ensure pharmacological parameters. Biosimilars have been introduced for several disease categories in Europe, with cancer supportive therapies and biosimilars for filgrastim and erythropoietins among the most widely used. Extrapolation of biosimilars is allowed after establishing significant comparability with reference biologics in Europe.
Trends in Oncology Pharmaceuticals Business DevelopmentTim Opler
This presentation provides an overview of the evolving marketplace for oncology transactions and is a summary of discussion materials shared by Torreya at the Sachs Conference on September 26, 2019 in Basel, Switzerland.
Generic medicines play an essential role in increasing access to affordable medicines. They currently make up over half of all medicines by volume but only 18% of costs, and have generated €30 billion in savings for EU healthcare systems. However, greater utilization of generic medicines could double these savings. For generics to continue providing benefits, policies must ensure fair prices, a level playing field, and acceptable margins across the supply chain.
COVID-19 and its Impact on the Biopharma Financing and Deal EnvironmentTim Opler
The document provides an overview of the impact of the COVID-19 pandemic on the biopharmaceutical sector. It discusses the direct impact on the pharmaceutical industry, including decreased healthcare utilization, clinical trial delays, supply chain issues, and decreased drug usage and revenue. It also covers the indirect effects, such as potential government budget constraints, drug price pressures, increased social division, and response from regulators to encourage testing and device approvals during the pandemic.
The pharmaceutical industry in Ukraine is growing rapidly but domestic production cannot keep up with market demands. Ukraine has a large population and territory, making it an attractive market for foreign pharmaceutical companies. The retail pharmaceutical market grows over 14% annually, fueled by increasing drug prices, though hospital segment growth is limited by state financing problems. Domestic producers focus on cheap mass drugs while foreign companies dominate the higher value market. AlexPharm is a Ukrainian pharmaceutical company established in 1994 as a joint venture with Pfizer. It markets over 30 products in therapeutic areas like gynecology, urology and cardiology through sales representatives and promotional activities. The company partners with major international pharmaceutical producers.
Austria In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Gene...ReportsnReports
This document provides a summary and analysis of the Austria In Vitro Diagnostics market from 2004-2018. It covers market segmentation and revenue for major categories including clinical chemistry, genetic testing, haematology, histology and cytology, immuno chemistry, infectious immunology, and microbiology culture. It also provides company profiles of major players in the Austria IVD market and details of partnerships, products in development, and other financial deals in the industry.
Chinese Markets for Anti-infectious Disease DrugsReportsnReports
This 198-page report examines China's market for anti-infectious disease drugs from 2012-2021. It provides historical data and forecasts of production, demand, imports, and exports. The report profiles major Chinese producers and assesses industry structure, capacity, and investments. It examines economic trends, the regulatory environment, supply and demand dynamics, and marketing strategies for the anti-infectious disease drugs industry in China. The report sells for a single-user license of $4000 and contains tables, charts, and profiles of key producers.
The Commonwealth of Independent States (CIS) region has a total GDP of approximately $1.6 trillion and a population of 276 million people. While the original drug market will grow more slowly than generics between 2010-2011, overall growth in original medicines will be positive. The pharmaceutical market is dominated by generic drugs, which make up around 85% of the market. Key players and market structure differ from Western markets, with almost a 50/50 split between Rx and OTC segments and strong local generic production, particularly in Ukraine.
The Vietnamese pharmaceutical market was valued at VND80,679 billion in 2014 and is expected to grow at a compound annual growth rate of 15.1% to reach VND139,832 billion by 2018. Currently over 50% of domestic demand is met through imports as domestic firms face competition from foreign companies with more advanced technology. However, Vietnam's growing and increasingly health-conscious population represents opportunities for future growth in the pharmaceutical industry. The top 10 listed pharmaceutical companies in Vietnam by market share are led by Vimedimex Medi-Pharma with a 14.6% share.
The global pharmaceutical market reached $942 billion in 2011 and is expected to reach $1.5 trillion by 2020 due to population growth and aging populations. The industry faces issues such as patent cliffs resulting in lost revenues, high research and development costs, and increasing government regulation. The Indian pharmaceutical industry has grown substantially over the past few decades and now supplies over 70% of the country's drug needs through branded generics. However, it faces weaknesses of stringent price controls, low investment in innovation, and quality concerns.
Pharmaceutical market india a comprehensive industry analysis - Reports CornerReports Corner
"1.0 Summary
“Pharmaceutical Market: India, A Competitive Industry Analysis” by Kelly Scientific Publications is a comprehensive report on the pharmaceutical and biotechnology industry in India and its impact on international markets. This report scrutinises top Indian pharmacos and their battle within domestic and international therapeutic markets. The business environment in which they compete is analysed as are key drivers, constraints, challenges and opportunities.
The Indian pharmaceutical market is set to become the eight largest pharma market globally by 2015. In 2012 it was worth $13 billion. It is forecast to reach $50 billion by 2015 and increase its dominance as a leading player in Asia. It is predicted that the Indian pharma market will be a significant global competitor by 2020 with an expected worth of up to $74 billion.
This report describes the current therapeutics that are propelling the biopharmaceutical market in India. It examines the current economic climate and how India compares to other emerging markets and also evolved markets such as the US and Europe. Current developments relating to patent expirations, government funding, and regulations are discussed. The emerging trends that appear in key sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines are elucidated and analysed.
This study reveals market figures of the overall Indian pharmaceutical market and sub-markets. Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry.
https://www.reportscorner.com/reports/15826/Pharmaceutical-Market:-India-A-Comprehensive-Industry-Analysis/
The document provides an overview of key statistics and trends for the European food and drink industry in 2011-2012. Some of the main points summarized are:
- The food and drink industry is the largest manufacturing sector in the EU in terms of turnover (€1,017 billion) and employment (4.25 million people).
- During the recent economic downturn, the industry sustained positive growth and employment levels remained steady, outperforming other EU manufacturing sectors.
- Small and medium-sized enterprises (SMEs) play a major role, accounting for 49.3% of industry turnover and 63.4% of employment.
- Top performing sub-sectors are meat, bakery, dairy
The document provides an in-depth 72-page report on the pharmaceutical market in Canada. It includes five-year projections of economic, demographic and pharmaceutical market indicators. It summarizes that the Canadian pharmaceutical market is projected to grow steadily through 2016 due to an aging population and commitment to healthcare, though government spending constraints could impact growth. It also notes that Canada has a strong domestic generic industry and pharmaceutical exports exceed $6 billion annually, driven partly by parallel trade with the US.
EU: Antibiotics - Market Report. Analysis And Forecast To 2020IndexBox Marketing
This document provides a sample summary of an EU antibiotics market report that analyzes the market from 2007-2015 and forecasts to 2020. It includes key findings on market volume, value, production, imports, and exports in 2015. The report also covers domestic production, trade balances, market structure by country, prices, trade channels, business environment, and company profiles. Tables and figures present data on these topics.
Each year, the U.S. biopharmaceutical industry spends billions of dollars on intensive research to discover new medicines for patients. Though the research process is long, uncertain, and expensive, the treatments that eventually result save lives and improve the health of people all around the world. Recent decades have seen enormous progress in the fight against major causes of death and disability, including cancer, HIV/AIDS, mental illness, and diabetes, as well as against numerous rare diseases. In addition, advances by companies in the biopharmaceutical sector play an important role in controlling costs of health care by reducing hospitalizations, surgeries, and other costly care.
Biopharmaceutical research and development is an investment in people, services, ideas and products.
This dynamic and innovative industry directly supports hundreds of thousands of jobs and indirectly supports millions more across the United States. The sector contributes significantly to the economy on the national, state, and local levels.
The 2012 Pharmaceutical Industry Profile explores the critical role that biopharmaceutical companies play in the lives of patients and in the U.S. economy. Chapter 1 describes recent advances in medicines and the value medicines bring to patients and the health care system. Chapter 2 discusses the positive economic impact of the industry and describes several key challenges facing the industry today. Chapter 3 describes major programs that ensure that people have access to the medicines they need.Chapter 4 explains the research and development (R&D) process and how the biopharmaceutical industry fits into the vibrant life sciences ecosystem. Through ongoing efforts to advance science and translate research findings into new medicines, biopharmaceutical companies bring value every day to patients, their families, and the entire economy.
This document discusses the value that innovative medicines provide to patients, healthcare systems, and society. It notes that patients are living longer, healthier lives thanks to new medicines, which also reduce costs in other parts of the healthcare system like hospitalizations. The biopharmaceutical industry generates economic value through job creation and R&D investment. However, the document also outlines challenges like increasing costs of drug development and regulatory hurdles that threaten continued innovation and access to medicines. It argues for outcomes-based approaches and partnerships to find solutions.
μιλία – παρουσίαση: Jim Sage, President PhRMA Innovation Forum, President and Managing Director, Pfizer Hellas
«Clinical Trials: A Potential Growth Engine For Greece. Key Considerations to Attract Clinical Trial Investment»
Market Research Report : Anti diabetic pharmaceuticals market in india 2015 -...Netscribes, Inc.
For the complete report, get in touch with us at: info@netscribes.com
Abstract :
Anti-diabetic pharmaceuticals market in India is considered to be one of the most lucrative diabetes markets in the world. Since India is the second largest diabetic pool in the world, after China, the market is characterized by a huge demand for anti-diabetic drugs. Huge increase in the number of diabetic patients promotes growth of the anti-diabetics pharmaceutical industry. The incidence of diabetes is higher in developed countries because of unhealthy lifestyles . Development of new and innovative drugs is also providing a boost to the market. Comprehensive health insurance coverage fuels the market growth by raising the affordability among patients. Increasing aging population in India increases the prevalence of diabetes, which in turn gives a boost to the drugs market.
However Price regulation in the insulin market and competition from alternative diabetes treatment hinders the growth of Anti-diabetic pharmaceuticals market in India. In spite of substantial demand-supply gap in the insulin market, foreign manufacturers and importers are facing a huge price challenge. Now-a-days People are becoming more aware of diabetes ,and are trying to move away from unhealthy sedentary lifestyles. Increasing awareness on part of the consumers are making them incorporate more physical exercises and avoid junk food. Such consciousness on part of the consumers is decreasing the growth of diabetes, which is limiting the growth of the anti-diabetic pharmaceutical market to some extent. The Indian Government, on its part, has introduced some diabetes control programmes. Various initiatives taken by the government is providing a boost to this market. The market is expected to exhibit steady growth over the next few years.
Table of Contents :
Slide 1: Executive Summary
Macroeconomic Indicators
Slide 2: GDP at Factor Cost: Quarterly (2011-12 – 2014-15), Inflation Rate: Monthly (Dec 2014-Jan 2015 – Mar 2015-Apr 2015)
Slide 3: Gross Fiscal Deficit: Monthly (Feb 2014 – Jul 2014), Exchange Rate: Monthly (Dec 2014 – May 2015)
Slide 4: Lending Rate: Annual (2011-12 – 2014-15), Trade Balance: Annual (2011-12 – 2014-15), FDI: Annual (2009-10 – 2013-14)
Introduction
Slide 5: Types of diabetes
Slide 6: Classification of the diabetes market
Slide 7: Classes of anti-diabetic drugs
Market Overview
Slide 8: Global Anti-Diabetic Pharmaceuticals Market – Overview, Size & Growth
Slide 9: Indian Anti-Diabetic Pharmaceuticals Market – Overview, Size & Growth
Slide 10: Global Diabetes map
Drivers & Challenges
Slide 11: Summary
Slide 12-15: Key Drivers
Slide 16-17: Key Challenges
Government Initiatives
Slide 18: Government programmes
Market Value Chain
Slide 19: Pharmaceutical Value Chain
Slide 20: Multistage Drug Development Process
Regulation and Patents
Slide 21: Drug regulations
Slide 22-23: Drugs approved for marketing in India
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...Office of Health Economics
This research presented in a poster at HTAi 2019, Cologne (Germany) by a team of OHE and IHE researchers, estimates the value added by second generation antipsychotics over their life-cycle in the UK and Sweden. It concludes that considering the entire life-cycle, the value added by SGAs to the system is higher than the expected value estimated at launch. P&R decisions should consider how to measure, capture and take into account the value added by medicines over the long-run.
Author(s) and affiliation(s): Mikel Berdud (Office of Health Economics, London), Niklas Wallin-Bernhardsson (Institute for Health Economics, Stockholm), Bernarda Zamora (Office of Health Economics, London), Peter Lindgren (Institute for Health Economics, Stockholm), Adrian Towse (Office of Health Economics, London)
Event: HTAi 2019 Annual Meeting
Date: 18/06/2019
Location: Cologne, Germany
European union’s medical technology market by emanuel baisireEmanuel Baisire
The document discusses market entry strategies for medical equipment companies entering the European Union market. It analyzes exporting, strategic alliances, and joint ventures. A strategic alliance with a European firm is identified as the best option to gain market knowledge, establish distribution channels, share costs and risks, and comply with regulatory requirements. Manufacturing locally in Europe through the alliance would allow the company to benefit from lower capital costs and currency exchange rates.
Europe biosimilars market opportunity outlook 2020KuicK Research
Europe was the first market to allow commercialization of biosimilars. The European Commission passed legislation in 2004 creating an approval pathway for biosimilars. Safety and efficacy are main concerns for biosimilars in Europe, and the European Medicines Agency requires head-to-head comparisons to ensure pharmacological parameters. Biosimilars have been introduced for several disease categories in Europe, with cancer supportive therapies and biosimilars for filgrastim and erythropoietins among the most widely used. Extrapolation of biosimilars is allowed after establishing significant comparability with reference biologics in Europe.
Trends in Oncology Pharmaceuticals Business DevelopmentTim Opler
This presentation provides an overview of the evolving marketplace for oncology transactions and is a summary of discussion materials shared by Torreya at the Sachs Conference on September 26, 2019 in Basel, Switzerland.
Generic medicines play an essential role in increasing access to affordable medicines. They currently make up over half of all medicines by volume but only 18% of costs, and have generated €30 billion in savings for EU healthcare systems. However, greater utilization of generic medicines could double these savings. For generics to continue providing benefits, policies must ensure fair prices, a level playing field, and acceptable margins across the supply chain.
COVID-19 and its Impact on the Biopharma Financing and Deal EnvironmentTim Opler
The document provides an overview of the impact of the COVID-19 pandemic on the biopharmaceutical sector. It discusses the direct impact on the pharmaceutical industry, including decreased healthcare utilization, clinical trial delays, supply chain issues, and decreased drug usage and revenue. It also covers the indirect effects, such as potential government budget constraints, drug price pressures, increased social division, and response from regulators to encourage testing and device approvals during the pandemic.
The pharmaceutical industry in Ukraine is growing rapidly but domestic production cannot keep up with market demands. Ukraine has a large population and territory, making it an attractive market for foreign pharmaceutical companies. The retail pharmaceutical market grows over 14% annually, fueled by increasing drug prices, though hospital segment growth is limited by state financing problems. Domestic producers focus on cheap mass drugs while foreign companies dominate the higher value market. AlexPharm is a Ukrainian pharmaceutical company established in 1994 as a joint venture with Pfizer. It markets over 30 products in therapeutic areas like gynecology, urology and cardiology through sales representatives and promotional activities. The company partners with major international pharmaceutical producers.
Austria In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Gene...ReportsnReports
This document provides a summary and analysis of the Austria In Vitro Diagnostics market from 2004-2018. It covers market segmentation and revenue for major categories including clinical chemistry, genetic testing, haematology, histology and cytology, immuno chemistry, infectious immunology, and microbiology culture. It also provides company profiles of major players in the Austria IVD market and details of partnerships, products in development, and other financial deals in the industry.
Chinese Markets for Anti-infectious Disease DrugsReportsnReports
This 198-page report examines China's market for anti-infectious disease drugs from 2012-2021. It provides historical data and forecasts of production, demand, imports, and exports. The report profiles major Chinese producers and assesses industry structure, capacity, and investments. It examines economic trends, the regulatory environment, supply and demand dynamics, and marketing strategies for the anti-infectious disease drugs industry in China. The report sells for a single-user license of $4000 and contains tables, charts, and profiles of key producers.
The Commonwealth of Independent States (CIS) region has a total GDP of approximately $1.6 trillion and a population of 276 million people. While the original drug market will grow more slowly than generics between 2010-2011, overall growth in original medicines will be positive. The pharmaceutical market is dominated by generic drugs, which make up around 85% of the market. Key players and market structure differ from Western markets, with almost a 50/50 split between Rx and OTC segments and strong local generic production, particularly in Ukraine.
The Vietnamese pharmaceutical market was valued at VND80,679 billion in 2014 and is expected to grow at a compound annual growth rate of 15.1% to reach VND139,832 billion by 2018. Currently over 50% of domestic demand is met through imports as domestic firms face competition from foreign companies with more advanced technology. However, Vietnam's growing and increasingly health-conscious population represents opportunities for future growth in the pharmaceutical industry. The top 10 listed pharmaceutical companies in Vietnam by market share are led by Vimedimex Medi-Pharma with a 14.6% share.
The global pharmaceutical market reached $942 billion in 2011 and is expected to reach $1.5 trillion by 2020 due to population growth and aging populations. The industry faces issues such as patent cliffs resulting in lost revenues, high research and development costs, and increasing government regulation. The Indian pharmaceutical industry has grown substantially over the past few decades and now supplies over 70% of the country's drug needs through branded generics. However, it faces weaknesses of stringent price controls, low investment in innovation, and quality concerns.
Pharmaceutical market india a comprehensive industry analysis - Reports CornerReports Corner
"1.0 Summary
“Pharmaceutical Market: India, A Competitive Industry Analysis” by Kelly Scientific Publications is a comprehensive report on the pharmaceutical and biotechnology industry in India and its impact on international markets. This report scrutinises top Indian pharmacos and their battle within domestic and international therapeutic markets. The business environment in which they compete is analysed as are key drivers, constraints, challenges and opportunities.
The Indian pharmaceutical market is set to become the eight largest pharma market globally by 2015. In 2012 it was worth $13 billion. It is forecast to reach $50 billion by 2015 and increase its dominance as a leading player in Asia. It is predicted that the Indian pharma market will be a significant global competitor by 2020 with an expected worth of up to $74 billion.
This report describes the current therapeutics that are propelling the biopharmaceutical market in India. It examines the current economic climate and how India compares to other emerging markets and also evolved markets such as the US and Europe. Current developments relating to patent expirations, government funding, and regulations are discussed. The emerging trends that appear in key sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines are elucidated and analysed.
This study reveals market figures of the overall Indian pharmaceutical market and sub-markets. Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry.
https://www.reportscorner.com/reports/15826/Pharmaceutical-Market:-India-A-Comprehensive-Industry-Analysis/
The document provides an overview of key statistics and trends for the European food and drink industry in 2011-2012. Some of the main points summarized are:
- The food and drink industry is the largest manufacturing sector in the EU in terms of turnover (€1,017 billion) and employment (4.25 million people).
- During the recent economic downturn, the industry sustained positive growth and employment levels remained steady, outperforming other EU manufacturing sectors.
- Small and medium-sized enterprises (SMEs) play a major role, accounting for 49.3% of industry turnover and 63.4% of employment.
- Top performing sub-sectors are meat, bakery, dairy
The document provides an in-depth 72-page report on the pharmaceutical market in Canada. It includes five-year projections of economic, demographic and pharmaceutical market indicators. It summarizes that the Canadian pharmaceutical market is projected to grow steadily through 2016 due to an aging population and commitment to healthcare, though government spending constraints could impact growth. It also notes that Canada has a strong domestic generic industry and pharmaceutical exports exceed $6 billion annually, driven partly by parallel trade with the US.
EU: Antibiotics - Market Report. Analysis And Forecast To 2020IndexBox Marketing
This document provides a sample summary of an EU antibiotics market report that analyzes the market from 2007-2015 and forecasts to 2020. It includes key findings on market volume, value, production, imports, and exports in 2015. The report also covers domestic production, trade balances, market structure by country, prices, trade channels, business environment, and company profiles. Tables and figures present data on these topics.
Each year, the U.S. biopharmaceutical industry spends billions of dollars on intensive research to discover new medicines for patients. Though the research process is long, uncertain, and expensive, the treatments that eventually result save lives and improve the health of people all around the world. Recent decades have seen enormous progress in the fight against major causes of death and disability, including cancer, HIV/AIDS, mental illness, and diabetes, as well as against numerous rare diseases. In addition, advances by companies in the biopharmaceutical sector play an important role in controlling costs of health care by reducing hospitalizations, surgeries, and other costly care.
Biopharmaceutical research and development is an investment in people, services, ideas and products.
This dynamic and innovative industry directly supports hundreds of thousands of jobs and indirectly supports millions more across the United States. The sector contributes significantly to the economy on the national, state, and local levels.
The 2012 Pharmaceutical Industry Profile explores the critical role that biopharmaceutical companies play in the lives of patients and in the U.S. economy. Chapter 1 describes recent advances in medicines and the value medicines bring to patients and the health care system. Chapter 2 discusses the positive economic impact of the industry and describes several key challenges facing the industry today. Chapter 3 describes major programs that ensure that people have access to the medicines they need.Chapter 4 explains the research and development (R&D) process and how the biopharmaceutical industry fits into the vibrant life sciences ecosystem. Through ongoing efforts to advance science and translate research findings into new medicines, biopharmaceutical companies bring value every day to patients, their families, and the entire economy.
This document discusses the value that innovative medicines provide to patients, healthcare systems, and society. It notes that patients are living longer, healthier lives thanks to new medicines, which also reduce costs in other parts of the healthcare system like hospitalizations. The biopharmaceutical industry generates economic value through job creation and R&D investment. However, the document also outlines challenges like increasing costs of drug development and regulatory hurdles that threaten continued innovation and access to medicines. It argues for outcomes-based approaches and partnerships to find solutions.
μιλία – παρουσίαση: Jim Sage, President PhRMA Innovation Forum, President and Managing Director, Pfizer Hellas
«Clinical Trials: A Potential Growth Engine For Greece. Key Considerations to Attract Clinical Trial Investment»
Μάκης Παπαταξιάρχης - 6th Clinical Research ConferenceStarttech Ventures
Ομιλία: Μάκης Παπαταξιάρχης, Διευθύνων Σύμβουλος Janssen Ελλάδος, Pharmaceutical Companies of Johnson & Johnson, Πρόεδρος του PhRMA Innovation Forum, Πρόεδρος του AmCham Pharmaceutical Committee
Trailblazing scientists who are the backbone of our industry. These are the people that discover the molecules and develop the medicines to tackle the toughest diseases we face in society.
This document provides an outline for a report on the Indian pharmaceutical trade and distribution channels. It begins with an introduction to the large size and growth of the Indian pharma industry. Section 2 discusses the growth trends in pharma exports by region, country, and category. Section 3 covers favorable government policies supporting the industry. Section 4 notes declining imports. Sections 5-7 analyze the distribution channel in India and changes occurring. Sections 8-9 evaluate the distribution channel's effectiveness and efficiency. The document concludes with sections on potential improvements to the distribution model and an overview of emerging e-pharmacy models.
Healthcare & Pharmaceuticals Industry in Turkey by 2015FMC Group
The document provides an overview of the healthcare and pharmaceutical industries in Turkey. It notes that Turkey has over 1,500 hospitals and 200,000 beds, with the majority run by the Ministry of Health. The pharmaceutical industry is the 18th largest globally and 7th in Europe, with over $16 billion in annual sales. The government has ambitious targets to increase healthcare access and expenditures by 2023.
Pharmaceutical Industry Global & Indianprateek_floyd
The document discusses the global pharmaceutical industry. It provides data showing steady growth in global pharmaceutical sales from 2003-2012, with the US market accounting for the largest share. The top 10 pharmaceutical companies are also listed. R&D spending and trends in major markets like the US, Europe, and Japan are examined. Details are also provided about the large and growing pharmaceutical industries in India and their competitive advantages in generics manufacturing.
The value of early asset development and commercializationCello Health
Worldwide pharmaceutical R&D spend is increasing each year, and the competition for a share of that investment is becoming fiercer. Companies need to demonstrate the potential value of their asset in commercial as well as scientific and clinical terms.
The slides in this deck define and identify value from a financial, clinical and commercial perspective while also exploring how to derive value for patients.
Europe In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry, Gene...ReportsnReports
This report provides an in-depth analysis of the in vitro diagnostics market in Europe from 2004-2018. It examines market size and revenue for major categories like clinical chemistry, genetic testing, and hematology in countries like Germany, France, UK, Italy and Spain. The 445-page report includes historical data from 2004-2011, forecasts to 2018, and profiles of key companies in the market. It provides a comprehensive overview of market drivers, trends and opportunities for businesses in the European in vitro diagnostics space.
BioPharm Insight Fuelling the growth of EU Pharma and BiotechDr Jobin Shaeri
While Europe continues to produce promising life sciences innovation, European biotech and pharma companies struggle to attract meaningful early-stage investments from risk-averse European investors. This is due to smaller and more dilutive funding rounds in Europe compared to the US, leading many promising European companies to relocate or be acquired earlier. However, deal activity and market capitalization of major European companies have grown in recent years, and enthusiasm for innovation remains high, especially in areas like oncology, infectious diseases, and the central nervous system.
The data and analytics of the new life sciences marketplace handoutFrank Wartenberg
Trends in the global healthcare market. Development of pharmaceuticals, market data and insights.
Presentation delivered at the 9th International Pharmaceutical Compliance Congress and Best Practices Forum, Brussels, 2015
Portrait of the German Chemical and Pharmaceutical industryLorenzo Zullo
The document provides an overview of key statistics and trends in the German chemical and pharmaceutical industry from 1995 to 2015. It shows that the industry has grown in sales, exports, and R&D spending in this period. While Germany remains the largest chemical producer in Europe, growth rates in Asia have been higher in recent years. The industry is investing more abroad now than within Germany and shifting foreign investments toward Asia and Latin America. Germany ranks fourth globally in chemical production and second in chemical exports.
Future of the Global Pharmaceutical IndustryTim Opler
The global pharmaceutical industry is much larger than previously estimated and is projected to nearly triple in size by 2060. Torreya Partners estimates the current size of the global pharma sector to be $1.13 trillion based on their analysis of over 30,000 companies, which is 30% larger than other recent estimates. Their data indicates the industry is dominated by 17 large global companies that make up 45% of the value, with specialty pharma, China, generics, and Japan also representing significant portions of the total industry value. The pharmaceutical sector is one of the largest global industries and is projected to continue growing rapidly due to expanding global wealth and increasing healthcare spending.
China Healthcare Market potentials & opportunitiesritupon gogoi
China has a large and growing healthcare market due to its large population and strong economic growth. Healthcare expenditures as a percentage of GDP have been rising in China and are projected to reach $1 trillion by 2020. An aging population and rising rates of chronic diseases will drive further growth in healthcare spending. However, the Chinese healthcare market faces challenges from frequent changes in regulations, policies that favor domestic generic drugs over innovative medicines, and difficulties for foreign companies to gain inclusion on the national drug reimbursement list.
Healthcare & Pharmaceuticals Industry in Turkey by 2014FMC Group
Brief information about Turkish healthcare & pharmaceuticals industry by 2014 including number of hospitals and beds, healthcare transformation program and government targets for healthcare indicators
Sanofi reported results for Q3 2015 with sales growing 3.4% at constant exchange rates. Business EPS grew 6.1% at constant exchange rates. While diabetes sales declined 6.6% due to lower sales of Lantus in the US, other businesses such as Genzyme, vaccines, and Merial showed solid sales growth. Praluent was launched in the US and Europe for cholesterol treatment.
This document provides an overview and summary of the state of biotechnology in Europe from 2014-2015. It discusses that 2014 was an exceptional year for investment in European biotech, with almost 2.5 billion euros invested and 15 companies going public. However, it notes there remains a question mark over Europe as the regulatory framework is less predictable than other regions and the EU needs to do more to ensure access to biotech products. The document advocates that European leaders must address remaining issues to ensure biotech can deliver on its potential for growth, jobs and societal solutions in Europe.
Basic Candlestick Pattern in stock market, financeGuru Balaji .S
The document provides information on various candlestick patterns used in technical analysis of financial markets. It begins with definitions of basic candlestick types like doji and hanging man candles. It then outlines several reversal patterns like morning star and engulfing patterns that indicate a change in trend. Continuation patterns like rising three methods and falling three methods that suggest the current trend will persist are also discussed. The document provides illustrations and explanations of many common candlestick patterns to help readers understand how to interpret these visual representations of market price action.
This document outlines various types and uses of purified water in pharmaceutical applications. It discusses drinking water that meets EPA or international standards which can be used directly if compatible. It then lists several typical water treatment steps like deionization, reverse osmosis, and distillation used to produce purified water for special pharmaceutical purposes like API processes. The document categorizes purified water products for uses such as hemodialysis, analytical reagents, cleaning/ingredients for non-parenteral dosage forms, and various sterile purified waters for injection, irrigation, inhalation after additional packaging and sterilization steps.
The document is an international patent application for pharmaceutical compositions of ibuprofen or its pharmaceutically acceptable salts. It summarizes various challenges with producing stable ibuprofen formulations, such as poor compressibility and adhesion during processing. The invention claims to provide a cost-effective method of producing ibuprofen granules with good flow properties and minimal weight variation through the use of glidants in three stages of formulation. It seeks patent protection for pharmaceutical compositions of ibuprofen and the process for their production.
The document outlines the process for registering a pharmaceutical product in the USA, which includes developing and testing the product, submitting an ANDA application to the FDA for approval, producing validation batches at a larger scale once approved, launching the product commercially, undergoing facility inspections by the FDA periodically for compliance.
This document discusses critical material attributes (CMA), critical process parameters (CPP), and critical quality attributes (CQA) for various pharmaceutical unit operations used in manufacturing oral solid dosage forms. It provides examples of CMAs, CPPS, and CQAs for common processes like blending, granulation, drying, compaction, and tableting. The goal is to identify material traits and processing conditions that most impact the critical quality standards of the finished drugs.
Specifications of process parameters and general ipc and finish product controlsGuru Balaji .S
This document outlines the critical process parameters and quality controls for various stages of manufacturing injectable products. It lists 7 key stages: 1) materials preparation, 2) compounding, 3) filtration, 4) filling, 5) lyophilization (if applicable), 6) final sterilization (if required), and 7) inspection. For each stage, critical process parameters are defined relating to temperature, time, pressure, flow rates, and other factors. Quality attributes of intermediate and finished products are also specified, including assays, pH, bacterial counts, and other attributes to ensure quality.
This document discusses process validation. It defines process validation as establishing documented evidence that a process will consistently produce a product meeting its predetermined specifications. The key aspects of process validation are to obtain consistent and reliable data, demonstrate that the process remains in control, and show the process works as intended. There are different types of process validation including prospective, retrospective, and concurrent validation. Process validation involves multiple phases from process design and qualification to process verification and monitoring. It is important for quality, safety, efficacy and compliance with global regulatory agencies.
The document describes the five modules of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Common Technical Document (CTD) format for ASEAN countries. Module 1 contains regional administrative information. Module 2 provides an overall summary of Modules 3, 4, and 5, including quality, non-clinical, and clinical overviews. Module 3 includes chemistry, manufacturing, and quality control documents. Module 4 contains non-clinical safety data. Module 5 provides clinical study reports, though generics only need to include bioequivalence studies. The CTD format is required for both new drug and generic applications in ASEAN countries.
Points to be considered in topical formulation designGuru Balaji .S
This document outlines key points to consider in topical formulation design, including the drug substance, excipients, physicochemical properties, container closure system, chemical and physical stability, manufacturability and scalability, preservative efficacy, and patient acceptance. Some important considerations are the quality and physical characteristics of the active pharmaceutical ingredient and excipients, ensuring compatibility between ingredients, and establishing a target product profile that maintains consistency of the formulation over time. Process parameters and equipment must also be identified during development to enable scalability and reproducibility of the commercial manufacturing process.
The document discusses requirements for new drug applications and abbreviated new drug applications for topical products. A full NDA requires extensive safety studies including toxicity, skin irritation, and sensitization testing as well as two clinical efficacy studies and manufacturing controls. An ANDA for generic topical products requires abbreviated safety testing for skin irritation and toxicity along with manufacturing controls and either in vivo bioequivalence studies or in vitro release testing, and qualitatively and quantitatively matching inactive ingredients.
IND refers to investigational new drugs used in clinical trials. NDA and BLA are for approval of new drugs and biologics respectively, requiring clinical data. ANDA is an abbreviated application for generic drugs, needing bioequivalence data. OTC drugs are approved via monographs without premarket review or the orange/purple book.
Pharmaceutical QbD concepts for drug developmentGuru Balaji .S
The document discusses quality by design (QbD) in pharmaceutical development. It defines QbD as a systematic approach that begins with predefined objectives and emphasizes product and process understanding based on science and risk management. Under QbD, the desired product performance profile, target product quality attributes, and critical material attributes are defined to identify and control sources of variability. QbD provides increased flexibility while maintaining quality standards compared to traditional quality testing approaches. Key aspects of implementing QbD include knowledge management, risk management, designing controls based on scientific understanding, and continual improvement using knowledge gained over a product's lifecycle.
Generic product development with QbD pathwayGuru Balaji .S
This document outlines the key steps for generic drug product development using a Quality by Design (QbD) pathway, including supplier selection, API and excipient compatibility studies, process development from lab to pilot to pivotal scale, formula optimization at each stage, manufacturing demonstration batches, biostudies, stability testing, and e-CTD regulatory submission with defined quality target product profile, critical quality attributes, critical material attributes, and control strategy.
This particular slides consist of- what is hypotension,what are it's causes and it's effect on body, risk factors, symptoms,complications, diagnosis and role of physiotherapy in it.
This slide is very helpful for physiotherapy students and also for other medical and healthcare students.
Here is the summary of hypotension:
Hypotension, or low blood pressure, is when the pressure of blood circulating in the body is lower than normal or expected. It's only a problem if it negatively impacts the body and causes symptoms. Normal blood pressure is usually between 90/60 mmHg and 120/80 mmHg, but pressures below 90/60 are generally considered hypotensive.
Healthy Eating Habits:
Understanding Nutrition Labels: Teaches how to read and interpret food labels, focusing on serving sizes, calorie intake, and nutrients to limit or include.
Tips for Healthy Eating: Offers practical advice such as incorporating a variety of foods, practicing moderation, staying hydrated, and eating mindfully.
Benefits of Regular Exercise:
Physical Benefits: Discusses how exercise aids in weight management, muscle and bone health, cardiovascular health, and flexibility.
Mental Benefits: Explains the psychological advantages, including stress reduction, improved mood, and better sleep.
Tips for Staying Active:
Encourages consistency, variety in exercises, setting realistic goals, and finding enjoyable activities to maintain motivation.
Maintaining a Balanced Lifestyle:
Integrating Nutrition and Exercise: Suggests meal planning and incorporating physical activity into daily routines.
Monitoring Progress: Recommends tracking food intake and exercise, regular health check-ups, and provides tips for achieving balance, such as getting sufficient sleep, managing stress, and staying socially active.
About this webinar: This talk will introduce what cancer rehabilitation is, where it fits into the cancer trajectory, and who can benefit from it. In addition, the current landscape of cancer rehabilitation in Canada will be discussed and the need for advocacy to increase access to this essential component of cancer care.
2024 HIPAA Compliance Training Guide to the Compliance OfficersConference Panel
Join us for a comprehensive 90-minute lesson designed specifically for Compliance Officers and Practice/Business Managers. This 2024 HIPAA Training session will guide you through the critical steps needed to ensure your practice is fully prepared for upcoming audits. Key updates and significant changes under the Omnibus Rule will be covered, along with the latest applicable updates for 2024.
Key Areas Covered:
Texting and Email Communication: Understand the compliance requirements for electronic communication.
Encryption Standards: Learn what is necessary and what is overhyped.
Medical Messaging and Voice Data: Ensure secure handling of sensitive information.
IT Risk Factors: Identify and mitigate risks related to your IT infrastructure.
Why Attend:
Expert Instructor: Brian Tuttle, with over 20 years in Health IT and Compliance Consulting, brings invaluable experience and knowledge, including insights from over 1000 risk assessments and direct dealings with Office of Civil Rights HIPAA auditors.
Actionable Insights: Receive practical advice on preparing for audits and avoiding common mistakes.
Clarity on Compliance: Clear up misconceptions and understand the reality of HIPAA regulations.
Ensure your compliance strategy is up-to-date and effective. Enroll now and be prepared for the 2024 HIPAA audits.
Enroll Now to secure your spot in this crucial training session and ensure your HIPAA compliance is robust and audit-ready.
https://conferencepanel.com/conference/hipaa-training-for-the-compliance-officer-2024-updates
Joker Wigs has been a one-stop-shop for hair products for over 26 years. We provide high-quality hair wigs, hair extensions, hair toppers, hair patch, and more for both men and women.
Let's Talk About It: Breast Cancer (What is Mindset and Does it Really Matter?)bkling
Your mindset is the way you make sense of the world around you. This lens influences the way you think, the way you feel, and how you might behave in certain situations. Let's talk about mindset myths that can get us into trouble and ways to cultivate a mindset to support your cancer survivorship in authentic ways. Let’s Talk About It!
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdfDr Rachana Gujar
Introduction: Substance use education is crucial due to its prevalence and societal impact.
Alcohol Use: Immediate and long-term risks include impaired judgment, health issues, and social consequences.
Tobacco Use: Immediate effects include increased heart rate, while long-term risks encompass cancer and heart disease.
Drug Use: Risks vary depending on the drug type, including health and psychological implications.
Prevention Strategies: Education, healthy coping mechanisms, community support, and policies are vital in preventing substance use.
Harm Reduction Strategies: Safe use practices, medication-assisted treatment, and naloxone availability aim to reduce harm.
Seeking Help for Addiction: Recognizing signs, available treatments, support systems, and resources are essential for recovery.
Personal Stories: Real stories of recovery emphasize hope and resilience.
Interactive Q&A: Engage the audience and encourage discussion.
Conclusion: Recap key points and emphasize the importance of awareness, prevention, and seeking help.
Resources: Provide contact information and links for further support.
Comprehensive Rainy Season Advisory: Safety and Preparedness Tips.pdfDr Rachana Gujar
The "Comprehensive Rainy Season Advisory: Safety and Preparedness Tips" offers essential guidance for navigating rainy weather conditions. It covers strategies for staying safe during storms, flood prevention measures, and advice on preparing for inclement weather. This advisory aims to ensure individuals are equipped with the knowledge and resources to handle the challenges of the rainy season effectively, emphasizing safety, preparedness, and resilience.
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to CareVITASAuthor
This webinar helps clinicians understand the unique healthcare needs of the LGBTQ+ community, primarily in relation to end-of-life care. Topics include social and cultural background and challenges, healthcare disparities, advanced care planning, and strategies for reaching the community and improving quality of care.
PET CT beginners Guide covers some of the underrepresented topics in PET CTMiadAlsulami
This lecture briefly covers some of the underrepresented topics in Molecular imaging with cases , such as:
- Primary pleural tumors and pleural metastases.
- Distinguishing between MPM and Talc Pleurodesis.
- Urological tumors.
- The role of FDG PET in NET.
Unlocking the Secrets to Safe Patient Handling.pdfLift Ability
Furthermore, the time constraints and workload in healthcare settings can make it challenging for caregivers to prioritise safe patient handling Australia practices, leading to shortcuts and increased risks.
2. EFPIA Key Data | 2017
2
THE PHARMACEUTICAL INDUSTRY:
A KEY ASSET TO SCIENTIFIC AND MEDICAL PROGRESS
Thanks to advances in science and technology, the
research-based pharmaceutical industry is entering
an exciting new era in medicines development.
Research methods are evolving and we have many
promising prospects on the horizon – from the
possibilities offered by personalised medicines, to
the potential offered by harnessing the power of
big data. The innovative pharmaceutical industry
is driven by, and drives, medical progress. It aims
to turn fundamental research into innovative
treatments that are widely available and accessible
to patients.
Already, the industry has contributed to significant
improvements in patient well-being. Today’s
European citizens can expect to live up to 30 years
longer than they did a century ago. Some major
steps in biopharmaceutical research, complimented
by many smaller steps, have allowed for reductions
in mortality, for instance from HIV/AIDS-related
causes and a number of cancers. High blood pressure
and cardiovascular disease can be controlled with
antihypertensive and cholesterol-lowering medicines;
knee or hip replacements prevent patients from
immobility; and some cancers can be controlled – or
even cured – with the help of new targeted treatments.
European citizens can expect not only to live longer,
but to live better quality lives. Yet major hurdles remain,
including Alzheimer’s, Multiple Sclerosis, many cancers,
and orphan diseases.
Source: HIV/AIDS
surveillance in
Europe 2015, WHO
Regional Office for
Europe & European
Centre for Disease
Prevention and
Control (ECDC),
2016
TOTAL NUMBER OF DEATHS AMONG AIDS CASES IN EUROPE (TOTAL EU/EEA)
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
0
1000
2000
3000
4000
3507 3451
3072
2595 2475 2394
2200 2243
1342
991
3. 3
INDUSTRY (EFPIA total) 2000 2010 2015 2016
Production 127,504 199,400 238,437 250,000 (e)
Exports (1) (2) 90,935 276,357 365,303 375,000 (e)
Imports 68,841 204,824 269,012 275,000 (e)
Trade balance 22,094 71,533 96,291 100,000 (e)
R&D expenditure 17,849 27,920 33,557 35,000 (e)
Employment (units) 554,186 670,088 739,499 745,000 (e)
R&D employment (units) 88,397 117,035 113,713 115,000 (e)
Total pharmaceutical market value
at ex–factory prices
89,449 153,685 193,742 202,000 (e)
Payment for pharmaceuticals
by statutory health insurance systems
(ambulatory care only)
76,909 129,464 131,685 134,000 (e)
THE PHARMACEUTICAL INDUSTRY: A KEY ASSET TO THE
EUROPEAN ECONOMY
As well as driving medical progress by researching,
developing and bringing new medicines that
improve health and quality of life for patients around
the world, the research-based pharmaceutical
industry is a key asset of the European economy.
It is one of Europe’s top performing high-technology
sectors.
Values in € million unless otherwise stated
(1) Data relate to EU–27, Norway and Switzerland since 2005 (EU–15 before 2005); Croatia and Serbia included since 2010;
Turkey included since 2011; Russia included since 2013
(2) Data relating to total exports and total imports include EU–28 intra–trade (double counting in some cases)
Source: EFPIA member associations (official figures) – (e): EFPIA estimate; Eurostat (EU–28 trade data 2000-2016)
4. EFPIA Key Data | 2017
4
64.7%
9.4%
7.3%
17.5%
Pharmerging
Japan
Europe
(Top 5)
Rest of
the World
USA
1.1%
MAIN TRENDS
The research-based pharmaceutical industry can
play a critical role in restoring Europe to growth and
ensuring future competitiveness in an advancing
global economy. In 2016 it invested an estimated €
35,000 million in RD in Europe. It directly employs
some 745,000 people and generates three to four
times more employment indirectly – upstream and
downstream – than it does directly. However, the
sector faces real challenges. Besides the additional
regulatory hurdles and escalating RD costs, the
sector has been severely hit by the impact of fiscal
austerity measures introduced by governments
across much of Europe since 2010.
There is rapid growth in the market and research
environment in emerging economies such as
Brazil, China and India, leading to a gradual
migration of economic and research activities
from Europe to these fast-growing markets. In
2016 the Brazilian and Chinese markets grew
by 10.0% and 6.9% respectively compared to
an average market growth of 4.5% for the total
European Union market and 6.3% for the US
market (source: IMS Health, May 2017).
In 2016 North America accounted for 49.0% of
world pharmaceutical sales compared with 21.5%
for Europe. According to IMS Health data (MIDAS
May 2017), 64.7% of sales of new medicines
launched during the period 2011-2016 were on
the US market, compared with 17.5% on the Eu-
ropean market (top 5 markets).
The fragmentation of the EU pharmaceutical
market has resulted in a lucrative parallel trade.
This benefits neither social security nor patients
and deprives the industry of additional resources
to fund RD. Parallel trade was estimated to
amount to € 5,361 million (value at ex-factory
prices) in 2015.
GEOGRAPHICAL BREAKDOWN (BY MAIN MARKETS) OF SALES OF NEW MEDICINES LAUNCHED DURING THE
PERIOD 2011–2016
Note:
New medicines cover all new
active ingredients marketed
for the first time on the world
market during the period
2011-2016
Europe (Top 5) comprises
Germany, France, Italy, Spain
and United Kingdom
Pharmerging comprises
21 countries ranked by IMS
Health as high–growth
pharmaceutical markets
(Algeria, Argentina, Bangladesh,
Brazil, Colombia, Chile, China,
Egypt, India, Indonesia,
Kazakhstan, Mexico, Nigeria,
Pakistan, Philippines, Poland,
Russia, Saudi Arabia, South
Africa, Turkey and Vietnam)
Source: IMS Health
(MIDAS May 2017)
5. 5
PHARMACEUTICAL RD EXPENDITURE IN EUROPE, USA AND JAPAN (MILLION OF NATIONAL CURRENCY
UNITS*), 1995-2015
* Note:Europe:€million;USA:$million;Japan:¥millionx100
(e): estimate
Source: EFPIA member associations, PhRMA, JPMA
SHARE OF PARALLEL IMPORTS IN PHARMACY MARKET SALES (%) – 2015
Note:U.K.:in%ofpharmacymarketsalesatconsumer/retailprices
Source: EFPIA member associations (estimate)
0,000
10,000
20,000
30,000
40,000
50,000
20152010200520001995
11,484 11,874
6,422
17,849
21,988
30,969
10,477
33,557
47,051 (e)
21,364
7,462
27,920
40,688
12,760
14,577
Europe USA Japan
0
2
4
6
8
10
12
14
16
18
20
22
24
26
U.K.SwedenPolandNetherlandsIrelandGermanyDenmarkBelgiumAustria
1,3 1,7
24,9
9,0
7,0 8,2
1,7
12,0
9,0
6. EFPIA Key Data | 2017
6
PHARMACEUTICAL INDUSTRY RESEARCH
AND DEVELOPMENT IN EUROPE
All new medicines introduced into the market are
the result of lengthy, costly and risky research and
development (RD) conducted by pharmaceutical
companies:
By the time a medicinal product reaches the market,
an average of 12-13 years will have elapsed since
the first synthesis of the new active substance;
The cost of researching and developing a new
chemical or biological entity was estimated at
€ 1,926 million ($ 2,558 million in year 2013
dollars) in 2016 (DiMasi et al, Journal of Health
Economics, January 2016);
On average, only one to two of every 10,000
substances synthesised in laboratories will
successfully pass all stages of development
required to become a marketable medicine.
PHASES OF THE RESEARCH AND DEVELOPMENT PROCESS
Screening(10,000molecules)
0 5 years
Patent application Pre–clinical
developm
ent
Clinical trials
Acute toxicity
Pharm
acology
Chronic toxicity
Phase I
Phase II
Phase III
Price
Reim
bursem
ent
Pharm
acovigilance
Registration
/ M
arketing
authorisation
10 years
10 years of RD 2 to 3 years of
administrative procedures
15 years 20 years
patent expiry
25 years
SPC (supplementary protection
certificate) max. + 5 years
1 medicinal product
7. 7
PHARMACEUTICAL INDUSTRY RESEARCH AND DEVELOPMENT IN EUROPE
EFPIA 2015 € million € million
Austria 285
Belgium 2,589
Bulgaria n.a
Croatia 40
Cyprus 85
Czech Rep. 77
Denmark 1,497
Estonia n.a
Finland 172
France 4,564
Germany 6,216
Greece 80
Hungary 179
Iceland n.a
Ireland 305
Italy 1,415
Latvia n.a
Lithuania n.a
Malta n.a
Netherlands 642
Norway 126
Poland 308
Portugal 75
Romania 98
Russia 251
Slovakia n.a
Slovenia 183
Spain 908
Sweden 1,104
Switzerland 6,525
Turkey 77
U.K. 5,756
TOTAL 33,557
Note:
The figures relate to the RD carried out in each country.
Portugal, France: 2014 data; Austria, Cyprus, Greece, Hungary, Ireland, Slovenia: 2013 data; Czech Republic: 2012 data; Croatia,
Netherlands: 2011 data
Belgium, Croatia, Denmark, France, Germany, Greece, Ireland, Italy, Netherlands, Norway (LMI members), Poland, Romania,
Slovenia, Sweden (LIF members), Switzerland (Interpharma members), Turkey: estimate
Source: EFPIA member associations (official figures)
8. EFPIA Key Data | 2017
8
Allocation of RD investments by function (%)
21.2
48.3
5.1
16.6
8.9
Pre-human/Pre-clinical
Approval
Pharmacovigilance (Phase IV)
Uncategorized
8.9
10.7
28.7
Phase I
Phase II
Phase III
Clinical Trials
Europe USA Japan Others
0
20
40
60
80
100
2012-20162007-20112002-20061997-2001
79
46
67
21
14
52
75
88
32
38
65
20
12
84
29
4
Source: PhRMA, Annual Membership Survey
2016 (percentages calculated from 2014
data; total values may be affected
by rounding)
Source: SCRIP – EFPIA calculations (according to nationality of mother company)
ALLOCATION OF RD INVESTMENTS BY FUNCTION (%)
NUMBER OF NEW CHEMICAL OR BIOLOGICAL ENTITIES (1997-2016)
9. 9
Pharmaceutical RD expenditure - Annual growth rate (%)
Europe
USA
0
2
4
6
8
10
2012-20162007-20112002-2006
5.9
7.7
3.1
1.8
3.7
6.8
IMPORTANCE OF
PHARMACEUTICAL RD
In 2015 the pharmaceutical industry invested nearly
€ 33,600 million in RD in Europe. A decade of strong
US market dominance led to a shift of economic
and research activity towards the US from 1995-
2005. Additionally, Europe is now facing increasing
competition from emerging economies: rapid
growth in the market and research environments in
countries such as Brazil and China are contributing
to the move of economic and research activities to
non-European markets. The geographical balance of
the pharmaceutical market – and ultimately the RD
base – is likely to shift gradually towards emerging
economies.
ESTIMATED FULL COST OF BRINGING A NEW
CHEMICAL OR BIOLOGICAL ENTITY TO MARKET
($ MILLION - YEAR 2013 $)
Source: Joseph. A. DiMasi, Henry G. Grabowski, Ronald W.Hansen,
Innovation in the pharmaceutical industry: New estimates of RD
costs, Journal of Health Economics, 47 (2016), 20–33
Note:USA:datarelatetotheperiod2012-2015
Source: : EFPIA, PhRMA
0
1970 -
early 1980s
100
200
300
400
500
600
700
800
900
1,000
1,100
1,200
1,300
1,400
1,500
1980 -
early 1990s
1990 -
mid 2000s
2000s -
mid 2010s
179
413
1,044
2,558
1,600
1,700
1,800
1,900
2,000
2,100
2,200
2,300
2,400
2,500
2,600
PHARMACEUTICAL RD EXPENDITURE – ANNUAL GROWTH RATE (%)
10. EFPIA Key Data | 2017
10
RANKING OF INDUSTRIAL SECTORS BY OVERALL SECTOR RD INTENSITY
(RD AS PERCENTAGE OF NET SALES – 2015)
According to EUROSTAT data, the pharmaceutical
industry is the high technology sector with the
highest added-value per person employed,
significantly higher than the average value for
high-tech and manufacturing industries. The
pharmaceutical industry is also the sector with
the highest ratio of RD investment to net sales.
According to the 2016 EU Industrial RD Investment
Scoreboard the pharmaceutical and biotechnology
sector amounts to 19.1% of total business RD
expenditure worldwide.
0 2 4 6 8 10 12 14 16
15.0%
10.6%
8.4%
5.9%
4.7%
4.3%
3.8%
3.6%
3.2%
2.9%
2.8%
Software computer services
Pharmaceuticals biotechnology
Technology hardware equipment
Automobiles parts
Electronic electrical equipment
Healthcare equipment services
4.3%General industrials
All industries
Industrial engineering
Leisure goods
Chemicals
Aerospace defence
Note:
Data relate to the top 2,500 companies with registered offices in the EU (590), Japan (356), the US (837), China (327) and the Rest of
the World (390), ranked by total worldwide RD investment (with investment in RD above € 21 million).
Source: The 2016 EU Industrial RD Investment Scoreboard, European Commission, JRC/DG RTD
11. 11
PHARMACEUTICAL PRODUCTION
EFPIA 2015 € million € million
Austria 2,864
Belgium 11,232
Bulgaria 121
Croatia 434
Cyprus 180
Czech Rep. n.a
Denmark 13,080
Estonia n.a
Finland 1,598
France 20,554
Germany 29,536
Greece 929
Hungary 2,933
Iceland n.a
Ireland 19,305
Italy 29,326
Latvia 120
Lithuania n.a
Malta n.a
Netherlands 6,180
Norway 745
Poland 2,964
Portugal 1,490
Romania 655
Russia 5,092
Slovakia n.a
Slovenia 1,354
Spain 15,213
Sweden 7,809
Switzerland 42,479
Turkey 2,931
U.K. 19,313
TOTAL 238,437
Note:
All data based on SITC 54
Ireland: 2014 data; Latvia, Romania: 2013 data; Norway: 2012 data; Cyprus, Netherlands: 2010 data
Croatia, Czech Republic, Denmark, France, Ireland, Italy, Netherlands, Norway, Portugal, Slovenia, Spain, Sweden, Switzerland:
estimate
Bulgaria, Croatia, Cyprus, France, Germany, Hungary, Ireland, Latvia, Norway, Poland, Portugal, Romania, Slovenia: veterinary
products excluded
Source: EFPIA member associations (official figures)
Graph 13 - à remplir
Efpia 2013
PHAR
12. EFPIA Key Data | 2017
12
EMPLOYMENT IN THE PHARMACEUTICAL INDUSTRY
The research-based pharmaceutical industry is
one of Europe’s major high-technology industrial
employers. Recent studies in some countries showed
that the research-based pharmaceutical industry
generates three to four times more employment
indirectly - upstream and downstream - than it
does directly. Further, a significant proportion of
these are valuable skilled jobs, for instance in the
fields of academia or clinical science, which can help
maintain a high-level knowledge base and prevent
a European“brain drain”.
EFPIA 2015 units units
Austria 14,140
Belgium 34,617
Bulgaria 10,500
Croatia 5,740
Cyprus 1,140
Czech Rep. 17,900
Denmark 26,963
Estonia 400
Finland 5,233
France 98,690
Germany 114,069
Greece 26,000
Hungary 23,000
Iceland n.a
Ireland 26,373
Italy 63,500
Latvia 1,971
Lithuania 1,220
Malta 445
Netherlands 12,000
Norway 3,800
Poland 29,700
Portugal 7,500
Romania 25,600
Russia n.a
Slovakia 3,000
Slovenia 8,961
Spain 38,677
Sweden 11,012
Switzerland 43,848
Turkey 22,000
U.K. 61,500
TOTAL 739,499
Note:
Croatia, Czech Republic, Ireland, Netherlands, Spain, Sweden: 2014 data; Denmark, Lithuania: 2013 data; Latvia: 2012 data;
Slovakia: 2011 data; Cyprus: 2007 data; Malta: 2004 data
Austria, Belgium, Bulgaria, Croatia, Estonia, France, Greece, Ireland, Italy, Malta, Netherlands, Norway, Poland, Romania, Slovenia,
Sweden, Switzerland, Turkey, United Kingdom: estimate
Source: EFPIA member associations (official figures)
13. 13
Note:
Data includes Turkey (since 2011), Croatia and Lithuania (since 2010), Bulgaria, Estonia and Hungary (since 2009), Czech Republic
(since 2008), Cyprus (since 2007), Latvia, Romania Slovakia (since 2005), Malta, Poland and Slovenia (since 2004)
Source: EFPIA member associations (official figures) – (e): EFPIA estimate
Note:
Data includes Greece Lithuania (since 2013), Bulgaria and Turkey (since 2012), Poland (since 2010), Czech Republic, Estonia and
Hungary (since 2009), Romania (since 2005) and Slovenia (since 2004)
Croatia, Cyprus, Latvia, Malta, Serbia, Slovakia: data not available
Source: EFPIA member associations – (e): EFPIA estimate
EMPLOYMENT IN THE PHARMACEUTICAL INDUSTRY (1990-2016)
EMPLOYMENT IN PHARMACEUTICAL RD (1990-2016)
2016
2015
2010
2005
2000
1995
1990
100,0000 200,000 300,000 400,000 500,000 600,000 700,000 800,000
500,879
500,699
554,186
636,763
670,088
739,499
745,000 (e)
2016
2015
2010
2005
2000
1995
1990
20,0000 40,000 60,000 80,000 100,000 120,000
76,126
82,618
88,397
100,726
117,035
113,713
115,000 (e)
14. EFPIA Key Data | 2017
14
PHARMACEUTICAL SALES
PRICE STRUCTURE
The world pharmaceutical market was worth an estimated € 763,101 million ($ 844,676 million) at ex-factory
prices in 2016. The North American market (USA Canada) remained the world’s largest market with a 49.0%
share, well ahead of Europe and Japan.
Distribution margins, which are generally fixed by governments, and VAT rates differ significantly from
country to country in Europe. On average, approximately one third of the retail price of a medicine reverts
to distributors (pharmacists and wholesalers) and the State.
Note:
Europe includes Turkey
and Russia; percentages
might not add up due to
rounding
Source: IMS Health
(MIDAS), May 2017 (data
relate to the 2016 audited
global retail and hospital
pharmaceutical market
at ex-factory prices)
Note:
Non-weighted average
for Europe (average
estimate for 23
countries)
Source: EFPIA member
associations
BREAKDOWN OF THE WORLD PHARMACEUTICAL MARKET – 2016 SALES
BREAKDOWN OF THE RETAIL PRICE OF A MEDICINE, 2015 (%)
66.0%
Manufacturer
19.2%
Pharmacist
4.8%
Wholesaler
10.0%
State (VAT and other taxes)
North America
(USA, Canada)
Europe
49.0%
21.5%
Japan
8.3%
Africa, Asia*
Australia
*Excluding Japan
16.4%
4.7%
America
Latin
15. 15
PHARMACEUTICAL MARKET VALUE
(at ex–factory prices)
Graph 17
Graph 18
Breakdown of the world p
Breakdo
North America
(USA, Canada)
44.5%
Latin
America
4.7%
EFPIA 2015 € million € million
Austria 3,550
Belgium 4,708
Bulgaria 937
Croatia 659
Cyprus 180
Czech Rep. 2,290
Denmark 2,306
Estonia 265
Finland 2,246
France 27,645
Germany 30,038
Greece 4,058
Hungary 2,133
Iceland 108
Ireland 1,818
Italy 22,703
Latvia 238
Lithuania 373
Malta 77
Netherlands 4,821
Norway 1,624
Poland 5,587
Portugal 2,933
Romania 2,633
Russia 13,271
Serbia 564
Slovakia 1,184
Slovenia 562
Spain 15,625
Sweden 3,809
Switzerland 5,040
Turkey 7,383
U.K. 22,375
TOTAL 193,742
Note:
Medicinal products as defined by Directive 2001/83/EEC
Cyprus, Denmark, Finland, Iceland, Latvia, Lithuania, Norway, Russia, Slovenia, Sweden: pharmaceutical market value at pharmacy
purchasing prices
Iceland: 2013 data; Serbia: 2011 data; Malta: 2007 data
Belgium, France, Germany, Ireland, Italy, Malta, Norway, Spain, United Kingdom: estimate
Source:
EFPIA member associations (official figures) – Latvia, Lithuania, Norway: IMS Health
The figures above are for pharmaceutical sales, at ex-factory prices, through all distribution channels
(pharmacies, hospitals, dispensing doctors, supermarkets, etc.), whether dispensed on prescription or
at the patient’s request. Sales of veterinary medicines are excluded.
16. EFPIA Key Data | 2017
16
VAT RATES APPLICABLE TO MEDICINES
The table below shows the VAT rates applied to medicines in European countries as of 1 January 2017.
Country Standard VAT rate (%) VAT rates applied to medicines
Prescription (%) OTC (%)
Austria 20,0 10,0 10,0
Belgium 21,0 6,0 6,0
Bulgaria 20,0 20,0 20,0
Croatia 25,0 5,0 5,0
Cyprus 19,0 5,0 5,0
Czech Rep. 21,0 10,0 10,0
Denmark 25,0 25,0 25,0
Estonia 20,0 9,0 9,0
Finland 24,0 10,0 10,0
France (1) 20,0 2,1 10,0
Germany 19,0 19,0 19,0
Greece 24,0 6,0 6,0
Hungary 27,0 5,0 5,0
Iceland 24,0 24,0 24,0
Ireland (2) 23,0 0-23,0 0-23,0
Italy 22,0 10,0 10,0
Latvia 21,0 12,0 12,0
Lithuania (3) 21,0 5,0 21,0
Luxembourg 17,0 3,0 3,0
Malta 18,0 0,0 0,0
Netherlands 21,0 6,0 6,0
Norway 25,0 25,0 25,0
Poland 23,0 8,0 8,0
Portugal 23,0 6,0 6,0
Romania 19,0 9,0 19,0
Russia 18,0 10,0 10,0
Serbia 20,0 10,0 10,0
Slovakia 20,0 10,0 10,0
Slovenia 22,0 9,5 9,5
Spain 21,0 4,0 4,0
Sweden 25,0 0,0 25,0
Switzerland 8,0 2,5 2,5
Turkey 18,0 8,0 8,0
U.K. 20,0 0,0 20,0
(1) France: reimbursable medicines 2.1%; non–reimbursable medicines 10.0% (2) Ireland: oral medication 0%; other medication 23%
(3) Lithuania: reimbursable medicines 5.0%; non–reimbursable medicines 21.0%
17. 17
GENERICS
The term ‘generic’ is widely used but its definition is
not always consistent between countries. Generics
are usually produced by a manufacturer who is not
the inventor of the original product, and are marketed
when intellectual property protection rights are
exhausted.
Note:
Croatia, Denmark, Estonia, Finland, Greece,
Hungary, United Kingdom: share of generics
in pharmacy market sales
Austria, Belgium, Bulgaria, France, Germany,
Ireland, Italy, Netherlands, Portugal, Slovenia,
Spain: share of generics in reimbursable
pharmacy market sales
Czech Republic, Poland, Romania, Russia,
Slovakia, Sweden, Switzerland, Turkey: share
of generics in total market sales
Cyprus, Iceland, Latvia, Lithuania, Malta,
Norway, Serbia: 2015 data not available
France: data relate only to those active
substances listed on the official list of
medicines
Definition: ‘generic’ means a medicine based
on an active substance that is out of patent
and which is marketed under a different
name from that of the original branded
medicine.
Source: EFPIA member associations
SHARE (ESTIMATE – IN %)
ACCOUNTED FOR BY GENERICS
IN PHARMACEUTICAL MARKET
SALES VALUE (AT EX–FACTORY
PRICES), 2015
0% 10% 20% 30% 40% 50% 60%
37.0
16.0
33.0
42.0
20.0
25.1
21.2
25.0
18.7
30.9
17.5
21.0
54.2
16.7
61.8
21.7
28.1
55.8
22.0
27.2
18.0
13.6
38.1
31.0
Austria
Belgium
Bulgaria
Croatia
Czech Republic
Denmark
Estonia
Finland
France
Germany
Greece
38.0Hungary
Ireland
Italy
Netherlands
Poland
Portugal
Romania
Russia
Slovakia
Slovenia
Sweden
22.3Spain
Switzerland
Turkey
United Kingdom
18. EFPIA Key Data | 2017
18
PHARMACEUTICAL EXPORTS
EFPIA 2015 € million € million
Austria 8,472
Belgium 41,003
Bulgaria 819
Croatia 562
Cyprus 255
Czech Republic 2,148
Denmark 11,537
Estonia 64
Finland 852
France 27,857
Germany 68,706
Greece 1,018
Hungary 4,448
Ireland 30,231
Italy 19,052
Latvia 332
Lithuania 632
Luxembourg 300
Malta 241
Netherlands 27,434
Norway 705
Poland 2,841
Portugal 920
Romania 851
Russia 277
Slovakia 480
Slovenia 2,413
Spain 10,934
Sweden 7,600
Switzerland 58,127
Turkey 849
United Kingdom 33,343
TOTAL 365,303
Note:
All data based on SITC 54
Norway: veterinary products excluded, 2014 data
Source: Eurostat (COMEXT database – May 2017)
Norway: Statistics Norway; Switzerland: Swiss Federal Customs Administration
19. 19
PHARMACEUTICAL IMPORTS
EFPIA 2015 € million € million
Austria 8,002
Belgium 34,694
Bulgaria 1,151
Croatia 803
Cyprus 222
Czech Republic 3,678
Denmark 3,592
Estonia 361
Finland 2,010
France 23,659
Germany 42,282
Greece 2,790
Hungary 3,647
Ireland 5,752
Italy 21,372
Latvia 510
Lithuania 964
Luxembourg 390
Malta 132
Netherlands 19,168
Norway 1,597
Poland 4,912
Portugal 2,360
Romania 2,614
Russia 6,873
Slovakia 1,660
Slovenia 1,059
Spain 13,826
Sweden 3,576
Switzerland 20,688
Turkey 4,165
United Kingdom 30,503
TOTAL 269,012
Note:
All data based on SITC 54
Norway: veterinary products excluded, 2014 data
Source: Eurostat (COMEXT database – May 2017)
Norway: Statistics Norway; Switzerland: Swiss Federal Customs Administration
20. EFPIA Key Data | 2017
20
PHARMACEUTICAL TRADE BALANCE
EFPIA 2015 € million € million
Austria 470
Belgium 6,309
Bulgaria -332
Croatia -241
Cyprus 33
Czech Republic -1,530
Denmark 7,945
Estonia -297
Finland -1,158
France 4,198
Germany 26,424
Greece -1,772
Hungary 801
Ireland 24,479
Italy -2,320
Latvia -178
Lithuania -332
Luxembourg -90
Malta 109
Netherlands 8,266
Norway -892
Poland -2,071
Portugal -1,440
Romania -1,763
Russia -6,596
Slovakia -1,180
Slovenia 1,354
Spain -2,892
Sweden 4,024
Switzerland 37,439
Turkey -3,316
United Kingdom 2,840
TOTAL 96,291
Note:
All data based on SITC 54
Norway: veterinary products excluded, 2014 data
Source: Eurostat (COMEXT database – May 2017)
Norway: Statistics Norway; Switzerland: Swiss Federal Customs Administration
Graph 25
Graph 24
EU -28 trade balanc
The European Union’s
10,000
20,000
30,000
40,000
50,000
60,000
0
55,337
33,611
-60,000
-50,000
-40,000
-30,000
-20,000
-10,000
-45,320
-44,497
2,980
18,13
21. 21
EU exports
42.0%
33.6%
USA Others
12.1%
38.9%
Switzerland
34.7%
11.4%
ChinaRussia
4.3%
-
Japan
6.1% 5.7%
- 3.9%
Israel
3.8%
-
Singapore
3.5%
-
EU imports
EU exportsEU imports EU exportsEU imports
68,662
26,504
-47,631
-63,963
-2,567
18,854
SITC 54 Pharmaceutical products
SITC 71 Power generating machinery and equipment
SITC 75 Office machines and computers
SITC 76 Telecommunication, sound, TV, video
SITC 77 Electrical machinery
SITC 87 Professional, scientific, controlling material
-70,000
-60,000
-50,000
-40,000
-30,000
-20,000
-10,000
0
10,000
20,000
30,000
40,000
50,000
60,000
70,000
80,000
Source: Eurostat, COMEXT database, May 2017
Source: Eurostat, COMEXT database, May 2017
EU-28 TRADE BALANCE - HIGH TECHNOLOGY SECTORS (€ MILLION) - 2016
THE EUROPEAN UNION’S TOP 5 PHARMACEUTICAL TRADING PARTNERS - 2016
23. 23
PAYMENT FOR PHARMACEUTICALS BY COMPULSORY
HEALTH INSURANCE SYSTEMS AND NATIONAL HEALTH
SERVICES (ambulatory care only)
EFPIA 2015 € million € million
Austria 2,628
Belgium 3,867
Bulgaria 330
Croatia 373
Cyprus 93
Czech Rep. 550
Denmark 772
Estonia 113
Finland 1,378
France 23,353
Germany 34,836
Greece 2,000
Hungary 1,001
Iceland 92
Ireland 1,501
Italy 8,477
Latvia 126
Lithuania 194
Malta n.a.
Netherlands 4,466
Norway 1,289
Poland 1,909
Portugal 1,183
Romania 1,153
Russia 1,694
Serbia 218
Slovakia 1,089
Slovenia 278
Spain 9,535
Sweden 2,013
Switzerland 4,985
Turkey 5,982
U.K. 14,217
TOTAL 131,685
Note:
Russia: 2014 data; Iceland, Lithuania: 2013 data;
France, Ireland, Netherlands, Norway, Sweden, United Kingdom: estimate
Source: EFPIA member associations (official figures)
24. EFPIA Key Data | 2017
24
CAUSES OF DEATH BY MAJOR DISEASE AREAS
IN EUROPE (EU–28)
Data Source: Eurostat, data relate to year 2014 (non-disease directly related causes of deaths: EFPIA calculations), May 2017
Diseases of the circulatory system
Malignant neoplasms
Diseases of the respiratory system
Diseases of the digestive system
37.2%
9.6%
26.1%
7.8%
4.3%
3.8%
2.9%
3.8%
1.9%
1.6%
0.5%
0.3%
0.2%
Mental and behavioural disorders
Diseases of the genitourinary system
Certain infectious and parasitic diseases
Diseases of the blood(-forming organs)
and immune mechanism disorders
Diseases of the skin and subcutaneous tissue
Others
Diseases of the musculoskeletal system
and connective tissues
Diseases of the nervous system
and the sense organs
Endocrine, nutritional
and metabolic diseases
25. 25
THE ADDED VALUE OF
MEDICINES IN HEALTHCARE
Medicines constitute only a small part of healthcare
costs with, on average, 15.8% of total health
expenditure in Europe being spent on pharmaceuticals
and other medical non-durables. In costly diseases
such as cancer and rheumatoid arthritis, medicines
account for even less than 10% of the total disease
costs. Medicines can also generate additional savings,
for example by substantially reducing costs in other
areas of healthcare, including hospital stays and long-
term care costs.
Source: OECD Health Statistics 2016, May 2017 – EFPIA
calculations (non-weighted average for 25 EU EFTA countries)
Source: Lichtenberg, F: Pharmaceutical
innovation and longevity growth
in 30 developing OECD and high–income
countries, 2000 – 2009 (2012)
Life Expectancy (years)
BREAKDOWN OF TOTAL HEALTH EXPENDITURE
IN EUROPE – 2014
CONTRIBUTION OF INNOVATIVE MEDICINES TO INCREASE IN LIFE EXPECTANCY (2000–2009)
15.8%35.9%48.3%
Outpatient care others
In-patient care (hospital)
Pharmaceuticals other medical
non-durables
Graph 29
Graph 30
Contribution of innovative medicines to increase in life expectancy
(2000-2009)
Breakdown of total health expenditure in Europe – 2012
16.9%36.6%46.5%
Outpatient care others
In-patient care (hospital)
Pharmaceuticals other medical
non-durables
2000 Other Contribution
of Innovative
Medicines
2009
77.0
76.5
76.0
75.5
75.0
74.5
74.0
73.5
73.0
72.5
0
27%
73%
+ 1.74 years
From 2000–2009, an improvement in population
weightedmeanlifeexpectancyatbirthof1.74years
was seen across 30 OECD countries.
Innovative medicines are estimated to have
contributed to 73% of this improvement once
other factors are taken into account (e.g. income,
education, immunisation, reduction in risk factors,
health system access).
26. 26
EFPIA Key Data | 2017
EFPIA MEMBER ASSOCIATIONS
ASSOCIATIONS WITH LIAISON STATUS
Austria
Fachverband der Chemischen
Industrie Österreichs (FCIO)
Belgium
Association Générale de
l’Industrie du Médicament
(pharma.be)
Denmark
Laegemiddelindustriforeningen
The Danish Association of the
Pharmaceutical Industry (Lif)
Finland
Lääketeollisuus ry
Pharma Industry Finland (PIF)
France
Les Entreprises du Médicament
(LEEM)
Germany
Verband Forschender
Arzneimittelhersteller (VfA)
Greece
Hellenic Association of
Pharmaceutical Companies (SFEE)
Ireland
Irish Pharmaceutical Healthcare
Association (IPHA)
Italy
Associazione delle Imprese del
Farmaco (Farmindustria)
Netherlands
Vereniging Innovatieve
Geneesmiddelen
Norway
Legemiddelindustrien (LMI)
Poland
Employers Union of Innovative
Pharmaceutical Companies
(Infarma)
Portugal
Associação Portuguesa da
Indústria Farmacêutica (Apifarma)
Russia
Association of International
Pharmaceutical Manufacturers
(AIPM)
Spain
Asociación Nacional Empresarial
de la Industria Farmacéutica
(Farmaindustria)
Sweden
Läkemedelsindustriföreningen
The Swedish Association of the
Pharmaceutical Industry (LIF)
Switzerland
Verband der forschender
pharmazeutischen Firmen der
Schweiz (Interpharma)
Turkey
Arastirmaci Ilac Firmalari Dernegi
(AIFD)
United Kingdom
The Association of the British
Pharmaceutical Industry (ABPI)
Bulgaria: Association of Research-based Pharmaceutical Manufacturers in Bulgaria (ARPharM)
Croatia: Innovative Pharmaceutical Initiative (IF!)
Cyprus: Cyprus Association of Pharmaceutical Companies (KEFEA)
Czech Republic: Association of Innovative Pharmaceutical Industry (AIFP)
Estonia: Association of Pharmaceutical Manufacturers in Estonia (APME)
Hungary: Association of Innovative Pharmaceutical Manufacturers (AIPM)
Latvia: Association of International Research-based Pharmaceutical Manufacturers (SIFFA)
Lithuania: The Innovative Pharmaceutical Industry Association (IFPA)
Malta: Maltese Pharmaceutical Association (PRIMA)
Romania: Association of International Medicines Manufacturers (ARPIM)
Serbia: Innovative Drug Manufacturers’Association (INOVIA)
Slovakia: Association of Innovative Pharmaceutical Industry (AIFP)
Slovenia: Forum of International Research and Development Pharmaceutical Industries (EIG)
Ukraine: Association of Pharmaceutical Research and Development (APRaD)
27. 27
MEMBER COMPANIES
Full Members
AbbVie
Almirall
Amgen
Astellas
AstraZeneca
Bayer
Biogen
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Chiesi Farmaceutici
Eli Lilly
GlaxoSmithKline
Grünenthal
Ipsen
Johnson Johnson
LEO Pharma
Menarini
Merck
Merck Sharp Dohme (MSD)
Novartis
Novo Nordisk
Pfizer
Pierre Fabre
Roche
Sanofi
Servier
Shire
Takeda
Teva
UCB
Affiliate Members
Bial
Daiichi-Sankyo
Eisai
Esteve
Lundbeck
Orion Pharma
Otsuka
The Medicines Company
Vifor Pharma
28. EFPIA (The European Federation of Pharmaceutical Industries and Associations)
represents the research-based pharmaceutical industry operating in Europe.
Founded in 1978, its members comprise 33 national pharmaceutical industry associations
and 40 leading pharmaceutical companies undertaking research, development and
manufacturing of medicinal products in Europe for human use.
Its mission is to promote pharmaceutical research and development and the best conditions
in Europe for companies to bring to market medicines that improve human health and
the quality of life around the world.
Through its membership, EFPIA represents the common views of more than 1,900 large, medium and
small companies including the entire European research-based pharmaceutical sector whose interests
also include a significant part of the generics and biosimilars segments. Two specialised groups have been
created within EFPIA to address specific issues relating to vaccines (Vaccines Europe) and the needs of
biopharmaceutical companies (EBE - European Biopharmaceutical Enterprises).
EFPIA
Leopold Plaza Building Rue du Trône 108
B–1050 Brussels Belgium
Tel.: +32.(0)2.626.25.55
www.efpia.eu info@efpia.eu
Further details about the Federation and its activities can be obtained from: